Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind active-controlled study of LW402 versus upadacitinib in moderate-to-severe atopic dermatitis
CTR20261235Phase 2Active
- Sponsor
- Shanghai Changsen Pharmaceutical
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lw402 in atopic dermatitis (AD), sponsored by Shanghai Changsen Pharmaceutical. Started May 2026; status: active.
02
Drugs
lw402
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20261235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261235.